Group 1 - The core point of the article is that 加科思-B (01167) has established a co-CEO system, with current Chairman and CEO Dr. Wang Yinxiang and current Chief Medical Officer Dr. Wang Yi sharing the CEO responsibilities, aiming to enhance global strategic planning and market expansion in innovative drug development [1] - Following the announcement, 加科思-B's stock price rose over 7% in early trading, with a current increase of 5.94% to HKD 7.31 and a trading volume of HKD 16.91 million [1] - 加科思-B has signed a capital increase and equity transfer agreement with 海松资本 and an industry partner, where 海松资本 will pay RMB 125 million as an initial payment and RMB 75 million as a milestone payment to acquire 80% of 加科瑞康, leading to a reduction of 加科思's stake in 加科瑞康 to 10% [1] Group 2 - The new management structure will allow Dr. Wang Yinxiang to continue leading the company's global strategic planning and major decision-making, while Dr. Wang Yi will focus on overseas market expansion, international collaboration, and clinical development [1] - The divestment of non-core assets will enable 加科思-B to concentrate more on the oncology sector and improve its cash flow [1]
加科思-B早盘涨超7% 公司设立联席首席执行官制度 此前主动剥离非核心资产